Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease

Alzheimer's and Dementia

Volumn 7, Issue 2, 2011, Pages 177-184

  Small, Gary ^a   Bullock, Roger ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Kingshill Research Centre   (United Kingdom)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Treatment

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITION; COGNITION; DAILY LIFE ACTIVITY; DEMENTIA; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYMPTOM; VOMITING;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; EARLY DIAGNOSIS; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 79952738250     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2010.03.016     Document Type: Review

References (56)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimer's Dement 2007;3:186-91. (Pubitemid 46825511)
2. Waldemar G, Phung KT, Burns A, Georges J, Hansen FR, Iliffe S, et al. Access to diagnostic evaluation and treatment for dementia in Europe. Int J Geriatr Psychiatry 2007;22:47-54. (Pubitemid 46117337)
3. Raschetti R, Maggini M, Sorrentino GC, Martini N, Caffari B, Vanacore N. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease. Eur J Clin Pharmacol 2005;61:361-8. (Pubitemid 41569310)
4. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007;14:e1-26.
5. Venkatesh K, Bullock R, Akbas A. Strategies to improve tolerability of rivastigmine: a case series. Curr Med Res Opin 2007;23:93-95. (Pubitemid 46191674)
6. Zaghi J, Goldenson B, Inayathullah M, Lossinsky AS, Masoumi A, Avagyan H, et al. Alzheimer disease macrophages shuttle amyloidbeta from neurons to vessels, contributing to amyloid angiopathy. Acta Neuropathol 2009;117:111-124.
7. Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004;61:1852-1856. (Pubitemid 39612945)
8. Boustani M, Peterson B, Hanson L, Harris R, Lohr KN. Screening for dementia in primary care: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2003;138:927-937.
9. Callahan CM, Hendrie HC, Tierney WM. Documentation and evaluation of cognitive impairment in elderly primary care patients. Ann Intern Med 1995;122:422-429.
10. Iliffe S, Robinson L, Brayne C, Goodman C, Rait G, Manthorpe J, et al. Primary care and dementia: 1. diagnosis, screening and disclosure. Int J Geriatr Psychiatry 2009;24:895-901.
11. Maeck L, Haak S, Knoblauch A, Stoppe G. Primary care physicians' attitudes related to cognition enhancers in early dementia: a representative eight-year follow-up study in Lower Saxony, Germany. Int J Geriatr Psychiatry 2008;23:415-421. (Pubitemid 351566339)
12. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2009;CD001191.
13. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 2006;CD001190.
14. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006;CD001747.
15. Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999;281:1401-1406. (Pubitemid 29190218)
16. Schneider LS, Farlow MR. Severity of AD and response to cholinergic therapy. Eur J Neurol 1996;3:238.
17. Burns A, Spiegel R, Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:243-249. (Pubitemid 38401128)
18. Arai T, Ikeda K, Akiyama H, Haga C, Usami M, Sahara N, et al. A high incidence of apolipoprotein E epsilon4 allele in middle-aged non-demented subjects with cerebral amyloid beta protein deposits. Acta Neuropathol 1999;97:82-84. (Pubitemid 29132649)
19. Small GW, Ercoli LM, Silverman DH, Huang SC, Komo S, Bookheimer SY, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2000;97:6037-6042. (Pubitemid 30367519)
20. Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, et al. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord 2006;21:353-363. (Pubitemid 43735680)
21. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261-2268. (Pubitemid 30416276)
22. Farlow M, Anand R, Messina J Jr, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000;44:236-241.
23. Grossberg G, Sadowsky C, Förstl H, Frolich L, Nagel J, Tekin S, et al. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord 2009;23:158-164.
24. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-244. (Pubitemid 29224502)
25. Anand R, Messina J, Hartman R. Dose-response effect of rivastigmine in the treatment of Alzheimer's disease. Int J Geriatr Psychopharmacol 2000;2:68-72. (Pubitemid 30417804)
26. Sadowsky C, Cummings J, Tekin S, Lane R. Achieving optimal therapeutic doses - rivastigmine (Exelon) patch and capsule. Poster presented at the 132nd Annual Meeting of the American Neurological Association, Washington, DC, October 7-10, 2007.
27. Singh G, Thomas SK, Arcona S, Lingala V, Mithal A. Treatment persistency with rivastigmine and donepezil in a large state medicaid program. J Am Geriatr Soc 2005;53:1269-1270. (Pubitemid 41632540)
28. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002;72:310-314.
29. Gauthier S. Long-term efficacy of cholinesterase inhibitors. Brain Aging 2002;2:9-22.
30. Hui JS, Wilson RS, Bennett DA, Bienias JL, Gilley DW, Evans DA. Rate of cognitive decline and mortality in Alzheimer's disease. Neurology 2003;61:1356-1361. (Pubitemid 37463370)
31. Kurz A, Farlow M, Quarg P, Spiegel R. Disease stage in Alzheimer disease and treatment effects of rivastigmine. Alzheimer Dis Assoc Disord 2004;18:123-128. (Pubitemid 39202187)
32. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 2001;15:375-390. (Pubitemid 32487994)
33. Jhee SS, Shiovitz T, Hartman RD, Messina J, Anand R, Sramek J, et al. Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine. Clin Neuropharmacol 2002;25:122-123. (Pubitemid 34411834)
34. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002;127:45-63. (Pubitemid 34778530)
35. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002;41:719-739. (Pubitemid 34948194)
36. Bullock R. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. Int J Clin Pract 2002;56:206-214. (Pubitemid 34477205)
37. Small GW, Kaufer D, Mendiondo MS, Quarg P, Spiegel R. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005;59:473-477. (Pubitemid 40467894)
38. Spencer CM, NobleRivastigmine S. A review of its use in Alzheimer's disease. Drugs Aging 1998;13:391-411. (Pubitemid 28523796)
39. Feldman HH, Lane R. Rivastigmine: a placebo-controlled trial of BID and TID regimens in patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007;78:1056-1063.
40. Oertel W, Ross J, Eggert K, Adler G. Rationale for transdermal drug administration in Alzheimer's disease. Neurology 2007;69(Suppl 1):S4-9.
41. Lefèvre G, Sȩdek G, Jhee S, Leibowitz MT, Huang HL, Enz A, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 2008;83:106-14.
42. Mercier F, Lefèvre G, Huang HL, Schmidli H, Amzal B, Appel-Dingemanse S. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin 2007;23:3199-204.
43. Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22:456-67. (Pubitemid 46831690)
44. Lee J-H. Effects of body weight on tolerability of rivastigmine transdermal patch. Presented at the 24th Conference of Alzheimer's Disease International. Singapore: Suntec; 2009.
45. Bullock R, Touchon J, Bergman H, Gambina G, He Y, Rapatz G, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin 2005;21:1317-27. (Pubitemid 41140736)
46. Small G, Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr Med Res Opin 2007;23:2705-13. (Pubitemid 350146408)
47. Winblad B, Kawata AK, Beusterien KM, Thomas SK, Wimo A, Lane R, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:485-91. (Pubitemid 46831693)
48. Weinstock M. Selectivity of cholinesterase inhibition. Clinical implications for the treatment of Alzheimer's disease. CNS Drugs 1999;12:307-23.
49. Amici S, Lanari A, Romani R, Antognelli C, Gallai V, Parnetti L. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmine. Mech Ageing Dev 2001;122:2057-62. (Pubitemid 32926754)
50. Davidsson P, Blennow K, Andreasen N, Eriksson B, Minthon L, Hesse C. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci Lett 2001;300:157-60. (Pubitemid 32168211)
51. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 2002;109:1053-65. (Pubitemid 34762344)
52. Darreh-Shori T, Almkvist O, Guan ZZ, Garlind A, Strandberg B, Svensson AL, et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002;59:563-72. (Pubitemid 34919991)
53. Darreh-Shori T, Meurling L, Pettersson T, Hugosson K, Hellstrom-Lindahl E, Andreasen N, et al. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. J Neural Transm 2006;113:1791-801. (Pubitemid 44657676)
54. Nordberg A, Darreh-Shori T, Peskind E, Soininen H, Mousavi M, Lane R. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Curr Alzheimer Res 2009;6:3-13.
55. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc 2003;51:1451-4. (Pubitemid 37259876)
56. Brodaty H, Pond D, Kemp NM, Luscombe G, Harding L, Berman K, et al. The GPCOG: a new screening test for dementia designed for general practice. J Am Geriatr Soc 2002;50:530-4. (Pubitemid 34229411)